{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2005-D-0208\" sorted by posted_date descending", "rows": [["FDA-2005-D-0208-0006", "FDA", "FDA-2005-D-0208", "Reference 2 - FDA Blood Products Advisory Committee Meeting, March 2000 [FDA-2005-D-0208-0004] - Transcript", "Supporting & Related Material", "REF-Reference Material (external attachments)", "2008-07-18T04:00:00Z", 2008, 7, null, null, "2008-07-18T20:39:43Z", null, 0, 0, "090000648067609f"], ["FDA-2005-D-0208-0007", "FDA", "FDA-2005-D-0208", "Reference 5 - Draft Guidance for Industry General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products, November 1998 [FDA-2005-D-0208-0004] - Draft Guidance Document", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2008-07-18T04:00:00Z", 2008, 7, null, null, "2008-07-18T20:40:36Z", null, 0, 0, "0900006480676155"], ["FDA-2005-D-0208-0014", "FDA", "FDA-2005-D-0208", "Reference 4 - Background Material  for NAD1[FDA-2005-D-0208-0002]", "Supporting & Related Material", "BKG-Background Material", "2008-07-18T04:00:00Z", 2008, 7, null, null, "2008-07-20T05:27:20Z", null, 0, 0, "0900006480441243"], ["FDA-2005-D-0208-0009", "FDA", "FDA-2005-D-0208", "Reference 17 - Guidance for Industry \"Community Acquired Pneumonia - Developing Antimicrobial Drugs for Treatment [FDA-2005-D-0208-0004] - Draft Guidance Document", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2008-07-18T04:00:00Z", 2008, 7, null, null, "2008-07-18T20:50:33Z", null, 0, 0, "0900006480676a57"], ["FDA-2005-D-0208-0011", "FDA", "FDA-2005-D-0208", "Reference 1 - Background Material  for NAD1[FDA-2005-D-0208-0002] - Draft Guidance Document", "Supporting & Related Material", "BKG-Background Material", "2008-07-18T04:00:00Z", 2008, 7, null, null, "2008-07-18T04:58:03Z", null, 0, 0, "0900006480441246"], ["FDA-2005-D-0208-0008", "FDA", "FDA-2005-D-0208", "Reference 16 - Guidance for Industry \"Acute Bacterial Meningitis - Developing Antimicrobial Drugs for Treatment [FDA-2005-D-0208-0004] - Draft Guidance Document", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2008-07-18T04:00:00Z", 2008, 7, null, null, "2008-07-18T20:46:02Z", null, 0, 0, "0900006480676990"], ["FDA-2005-D-0208-0010", "FDA", "FDA-2005-D-0208", "Background Material  for NAD1 [FDA-2005-D-0208-0002] - Reference List", "Supporting & Related Material", "BKG-Background Material", "2008-07-18T04:00:00Z", 2008, 7, null, null, "2008-07-18T04:58:02Z", null, 0, 0, "0900006480441247"], ["FDA-2005-D-0208-0005", "FDA", "FDA-2005-D-0208", "Reference 1 - FDA Blood Products Advisory Committee Meeting, March 1999, [FDA-2005-D-0208-0004] - Transcript", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2008-07-18T04:00:00Z", 2008, 7, null, null, "2008-07-18T20:38:29Z", null, 0, 0, "0900006480676030"], ["FDA-2005-D-0208-0012", "FDA", "FDA-2005-D-0208", "Reference 2 - Background Material  for NAD1[FDA-2005-D-0208-0002]", "Supporting & Related Material", "BKG-Background Material", "2008-07-18T04:00:00Z", 2008, 7, null, null, "2008-07-18T04:58:04Z", null, 0, 0, "0900006480441248"], ["FDA-2005-D-0208-0013", "FDA", "FDA-2005-D-0208", "Reference 3 - Background Material  for NAD1 Blood Products Advisory Committee Meeting, March 2000[FDA-2005-D-0208-0002]  - Transcript", "Supporting & Related Material", "BKG-Background Material", "2008-07-18T04:00:00Z", 2008, 7, null, null, "2008-07-18T04:58:05Z", null, 0, 0, "0900006480441245"], ["FDA-2005-D-0208-0004", "FDA", "FDA-2005-D-0208", "Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency", "Other", "Guidance", "2008-07-17T04:00:00Z", 2008, 7, "2008-07-17T04:00:00Z", null, "2024-11-12T04:21:43Z", null, 1, 0, "0900006480680037"], ["FDA-2005-D-0208-0003", "FDA", "FDA-2005-D-0208", "Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Availability", "Notice", "NAD-Notice of Availability of Data", "2008-07-17T04:00:00Z", 2008, 7, "2008-07-17T04:00:00Z", null, "2008-07-17T12:54:19Z", "E8-16395", 0, 0, "090000648067fb8d"], ["FDA-2005-D-0208-0002", "FDA", "FDA-2005-D-0208", "Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Draft Guidance Document", "Other", "GDL-Guidance (Supporting and Related Materials)", "2005-12-02T05:00:00Z", 2005, 12, null, null, "2008-07-18T05:20:46Z", null, 0, 0, "090000648044123a"], ["FDA-2005-D-0208-0001", "FDA", "FDA-2005-D-0208", "Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Availability", "Notice", "NAD-Notice of Availability of Data", "2005-12-02T05:00:00Z", 2005, 12, "2005-11-30T05:00:00Z", "2006-03-02T04:59:59Z", "2008-07-18T05:09:10Z", null, 0, 0, "0900006480441234"]], "truncated": false, "filtered_table_rows_count": 14, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 order by posted_date desc limit 101", "params": {"p0": "FDA-2005-D-0208"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2005-D-0208", "results": [{"value": "FDA", "label": "FDA", "count": 14, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2005-D-0208", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 10, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&document_type=Notice", "selected": false}, {"value": "Other", "label": "Other", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2005-D-0208", "results": [{"value": 2008, "label": 2008, "count": 12, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&posted_year=2008", "selected": false}, {"value": 2005, "label": 2005, "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&posted_year=2005", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "title", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&_facet=title"}, {"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&_facet=comment_start_date"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2005-D-0208&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 2822.3840040154755, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}